Cardiovascular Diseases

Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.

Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.

FDA approval brings Abbott’s TactiFlex Duo to AFib ablation, combining RF and pulsed field energy for tailored treatment in complex cases.

Shingrix (recombinant shingles vaccine) links to 9% lower cardiovascular disease burden in older adults over seven years, strengthening vaccination value beyond shingles prevention.

VESALIUS-CV shows Repatha (evolocumab) cuts all-cause death 20% in high-risk CVD patients, preventing future stroke and heart attack.

The FDA approved a Lerochol autoinjector and updated its label to reflect a lower risk of major cardiovascular events.

A draft ICER report found that baxdrostat and lorundrostat don't lower blood pressure more than older generics but do cost much more.

Novo Nordisk’s ziltivekimab lowers IL-6 heart inflammation but misses MACE reduction in ZEUS phase 3 CVD trial, with higher serious infections risk.

Epic Research finds 2026 cholesterol guidelines and PREVENT-ASCVD expand statin eligibility to 54.6%, reshaping hyperlipidemia prevention and cardiovascular diseases risk.

Already approved for familial chylomicronemia syndrome, Redemplo now shows efficacy in severe hypertriglyceridemia; Arrowhead plans a U.S. sNDA filing before year-end.

Enlicitide, a macrocyclic peptide that binds PCSK9 and blocks LDL receptor interaction, is the first oral PCSK9 inhibitor FDA-approved to lower LDL-C.

GLP-1 receptor agonists can help reduce inflammation and improve blood vessel function in patients with peripheral artery disease.

The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.

Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy.

Timely diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) could potentially reduce excess healthcare utilization and spending, according to a poster at AMCP annual meeting 2026 in Nashville.

A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid cardiomyopathy, with no new safety concerns identified.

The updated guidance emphasizes earlier intervention through lifestyle changes, expanded cholesterol testing including Lp(a) and coronary artery calcium scoring, and earlier use of medication.

AI-quantified breast arterial calcification independently predicts heart disease, adding value beyond standard risk scores and enabling earlier preventive care.

Juxtapid has been available to treat adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high levels of LDL cholesterol.

Dhruv S. Kazi, M.D., a cardiologist at Beth Israel Deaconess Medical Center, discusses the research he and his team have done to determine if semaglutide used as secondary prevention of cardiovascular disease is cost-effective.

Researchers say a modest price cut would make semaglutide cost-effective for secondary prevention of cardiovascular disease in the United States.

New research at Mount Sinai explains how influenza infections increase the risk of heart attack through a specific immune pathway.

Rural hospital study found text messaging intervention significantly improved medication adherence for heart failure patients, demonstrating that simple technology can reduce readmissions.

Myqorzo was approved in December to treat adults with obstructive hypertrophic cardiomyopathy. It is available through a REMS program and has a boxed warning about the risk of heart failure.

Elevated levels of lipoprotein(a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.